{"id":10292,"date":"2025-12-02T02:09:24","date_gmt":"2025-12-01T23:09:24","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10292"},"modified":"2025-12-02T02:09:24","modified_gmt":"2025-12-01T23:09:24","slug":"semaglutid-nedir-glp-1-reseptor-agonisti-olarak-etkisi-ve-obezite-tedavisindeki-yeri","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10292","title":{"rendered":"Semaglutid Nedir? GLP-1 Resept\u00f6r Agonisti Olarak Etkisi ve Obezite Tedavisindeki Yeri"},"content":{"rendered":"

Semaglutid Nedir? GLP-1 Resept\u00f6r Agonistleri Aras\u0131nda Neden \u00d6ne \u00c7\u0131k\u0131yor?<\/h2>\n

Semaglutid, insan glukagon benzeri peptid-1 (GLP-1) hormonuna yap\u0131sal olarak benzeyen, protein-peptit temelli<\/strong> bir ila\u00e7t\u0131r. GLP-1 resept\u00f6r agonisti s\u0131n\u0131f\u0131nda yer al\u0131r ve hem tip 2 diyabet hem de obezite tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir se\u00e7enek olarak kabul edilmektedir. K\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan farkl\u0131 olarak, semaglutid bir peptit yap\u0131l\u0131 biyolojik ila\u00e7<\/strong>t\u0131r; bu da hem etki mekanizmas\u0131n\u0131 hem de v\u00fccutta kal\u0131\u015f s\u00fcresini k\u00f6kten de\u011fi\u015ftirmektedir.<\/p>\n

\"\"<\/p>\n<\/p>\n

Semaglutid\u2019in en dikkat \u00e7ekici \u00f6zelli\u011fi, haftada tek doz enjeksiyonla veya g\u00fcnl\u00fck oral formuyla uzun s\u00fcreli ve kararl\u0131 bir GLP-1 aktivasyonu sa\u011flayabilmesidir. Bu sayede hem kan \u015fekeri kontrol\u00fc hem de i\u015ftah reg\u00fclasyonu \u00fczerinde g\u00fc\u00e7l\u00fc ve s\u00fcrd\u00fcr\u00fclebilir etkiler olu\u015fturur (doi:10.1056\/NEJMoa1607141)<\/strong>.<\/p>\n

Protein-Peptit Yap\u0131l\u0131 Bir \u0130la\u00e7 Olarak Semaglutid K\u00fc\u00e7\u00fck Molek\u00fcl \u0130la\u00e7lardan Nas\u0131l Farkl\u0131?<\/h2>\n

Klasik diyabet ve obezite ila\u00e7lar\u0131n\u0131n b\u00fcy\u00fck k\u0131sm\u0131 k\u00fc\u00e7\u00fck molek\u00fcl<\/strong> yap\u0131s\u0131ndad\u0131r; a\u011f\u0131zdan al\u0131nd\u0131klar\u0131nda h\u0131zla emilir, metabolize olur ve genellikle daha k\u0131sa s\u00fcre etkili olurlar. Semaglutid ise modifiye edilmi\u015f bir peptit yap\u0131s\u0131ndad\u0131r ve bu sayede:<\/p>\n

    \n
  • Y\u00fcksek \u00f6zg\u00fcll\u00fckle GLP-1 resept\u00f6r\u00fcne ba\u011flan\u0131r<\/strong> ve istenmeyen hedeflere tutunma riski daha d\u00fc\u015f\u00fckt\u00fcr.<\/li>\n
  • Alb\u00fcmin ba\u011flanmas\u0131 ve kimyasal modifikasyonlar<\/strong> sayesinde v\u00fccutta daha uzun s\u00fcre dola\u015f\u0131r, bu da haftal\u0131k dozlama imk\u00e2n\u0131 verir (doi:10.1111\/dom.12765)<\/strong>.<\/li>\n
  • K\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lara g\u00f6re hipoglisemi riski daha d\u00fc\u015f\u00fckt\u00fcr<\/strong>, \u00e7\u00fcnk\u00fc ins\u00fclin sal\u0131n\u0131m\u0131n\u0131 glukoz d\u00fczeyine ba\u011f\u0131ml\u0131 olarak art\u0131r\u0131r.<\/li>\n<\/ul>\n

    Bu \u00f6zellikler, semaglutid\u2019i sadece bir \u201czay\u0131flama i\u011fnesi\u201d olmaktan \u00e7\u0131kar\u0131p, protein-peptit temelli yeni nesil metabolik ila\u00e7<\/strong> kategorisine yerle\u015ftirir.<\/p>\n

    Semaglutid Obezite Tedavisinde Nas\u0131l \u00c7al\u0131\u015f\u0131r?<\/h2>\n

    Obezite, yaln\u0131zca kalori fazlas\u0131ndan ibaret de\u011fildir; i\u015ftah, tokluk sinyalleri, ba\u011f\u0131rsak hormonlar\u0131 ve beyin aras\u0131ndaki karma\u015f\u0131k bir a\u011f\u0131n bozulmas\u0131yla ili\u015fkilidir. Semaglutid bu a\u011f\u0131n merkezinde yer alan GLP-1 resept\u00f6rlerini hedef al\u0131r ve:<\/p>\n

      \n
    • Beyindeki i\u015ftah merkezlerinde<\/strong> (\u00f6zellikle hipotalamus) tokluk hissini art\u0131r\u0131r.<\/li>\n
    • Mide bo\u015falmas\u0131n\u0131 yava\u015flat\u0131r<\/strong>, b\u00f6ylece yemek sonras\u0131 uzun s\u00fcre tok hissetmeyi sa\u011flar.<\/li>\n
    • Yemek iste\u011fini ve \u201ccraving\u201d ataklar\u0131n\u0131 azalt\u0131r<\/strong>, \u00f6zellikle y\u00fcksek kalorili ve ya\u011fl\u0131 yiyeceklere olan e\u011filimi d\u00fc\u015f\u00fcr\u00fcr (doi:10.1038\/s41591-021-01324-6)<\/strong>.<\/li>\n<\/ul>\n

      STEP klinik \u00e7al\u0131\u015fmalar\u0131, obez bireylerde semaglutid tedavisinin v\u00fccut a\u011f\u0131rl\u0131\u011f\u0131nda %15\u2019e varan kay\u0131plar<\/strong> sa\u011flayabildi\u011fini g\u00f6stermi\u015ftir; bu oran, bir\u00e7ok klasik k\u00fc\u00e7\u00fck molek\u00fcl obezite ilac\u0131n\u0131n \u00fczerinde yer almaktad\u0131r (doi:10.1056\/NEJMoa2032183)<\/strong>.<\/p>\n

      Semaglutid ve K\u00fc\u00e7\u00fck Molek\u00fcl \u0130la\u00e7lar\u0131n Kilo Verme Etkisi Kar\u015f\u0131la\u015ft\u0131rmas\u0131<\/h2>\n

      Obezite tedavisinde kullan\u0131lan geleneksel k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar genellikle:<\/p>\n

        \n
      • Merkezi sinir sisteminde uyar\u0131c\u0131 etki ile i\u015ftah\u0131 bask\u0131lar,<\/li>\n
      • Ya\u011f emilimini azalt\u0131r veya<\/li>\n
      • Termogenezi art\u0131r\u0131r.<\/li>\n<\/ul>\n

        Bu ila\u00e7lar, kardiyovask\u00fcler yan etkiler, ba\u011f\u0131ml\u0131l\u0131k riski veya gastrointestinal tolerans sorunlar\u0131 gibi k\u0131s\u0131tlamalara sahip olabilir. Semaglutid ise:<\/p>\n

          \n
        • Fizyolojik bir hormonun (GLP-1) taklidi<\/strong> oldu\u011fu i\u00e7in v\u00fccutla daha uyumlu bir sinyal sunar.<\/li>\n
        • Kardiyovask\u00fcler riskte azalma<\/strong> ile ili\u015fkilendirilmi\u015f, hatta baz\u0131 \u00e7al\u0131\u015fmalarda maj\u00f6r kardiyovask\u00fcler olaylarda azalma bildirilmi\u015ftir (doi:10.1056\/NEJMoa1607141)<\/strong>.<\/li>\n
        • Diyabetik hastalarda hem HbA1c d\u00fc\u015f\u00fc\u015f\u00fc<\/strong> hem de belirgin kilo kayb\u0131<\/strong> sa\u011flar (doi:10.1016\/S0140-6736(17)31412-0)<\/strong>.<\/li>\n<\/ul>\n

          Bu nedenle semaglutid, obezite ve diyabet kesi\u015fiminde, protein-peptit yap\u0131l\u0131 ila\u00e7lar\u0131n k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lara g\u00f6re nas\u0131l bir paradigma de\u011fi\u015fimi yaratt\u0131\u011f\u0131n\u0131n somut bir \u00f6rne\u011fidir.<\/p>\n

          Semaglutid G\u00fcvenli mi? Yan Etkiler ve Uzun D\u00f6nem Perspektif<\/h2>\n

          Semaglutid genellikle iyi tolere edilen bir ila\u00e7t\u0131r; ancak \u00f6zellikle tedavinin ba\u015flang\u0131c\u0131nda baz\u0131 gastrointestinal yan etkiler<\/strong> g\u00f6r\u00fclebilir:<\/p>\n

            \n
          • Bulant\u0131<\/li>\n
          • Kusma<\/li>\n
          • \u0130shal veya kab\u0131zl\u0131k<\/li>\n
          • Kar\u0131n a\u011fr\u0131s\u0131<\/li>\n<\/ul>\n

            Bu yan etkiler \u00e7o\u011fu hastada zamanla hafifler ve dozun yava\u015f titrasyonu ile y\u00f6netilebilir. Nadir de olsa pankreatit ve safra kesesi problemleri bildirilmi\u015ftir; bu nedenle klinik takip \u00f6nemlidir (doi:10.1111\/dom.12765)<\/strong>.<\/p>\n

            Uzun d\u00f6nem veriler, semaglutid\u2019in sadece kilo kayb\u0131 sa\u011flamad\u0131\u011f\u0131n\u0131, ayn\u0131 zamanda kan bas\u0131nc\u0131, lipid profili ve karaci\u011fer ya\u011flanmas\u0131<\/strong> \u00fczerinde de olumlu etkiler g\u00f6sterebilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir. Bu da onu metabolik sendromun \u00e7ok boyutlu y\u00f6netiminde g\u00fc\u00e7l\u00fc bir aday haline getirir (doi:10.1016\/S0140-6736(21)01751-5)<\/strong>.<\/p>\n

            Semaglutid Gelece\u011fi: Protein-Temelli Metabolik \u0130la\u00e7lar\u0131n Yeni \u00c7a\u011f\u0131<\/h2>\n

            Semaglutid, GLP-1 resept\u00f6r agonistleri aras\u0131nda yaln\u0131zca bir ila\u00e7 de\u011fil, protein-peptit temelli metabolik tedavilerin \u00f6nc\u00fcs\u00fc<\/strong> olarak g\u00f6r\u00fclmektedir. Obezite, diyabet, kardiyovask\u00fcler hastal\u0131klar ve hatta alkol kullan\u0131m\u0131 bozuklu\u011fu gibi alanlarda yeni klinik \u00e7al\u0131\u015fmalar y\u00fcr\u00fct\u00fclmektedir. K\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n s\u0131n\u0131rlar\u0131na yakla\u015f\u0131ld\u0131\u011f\u0131 noktada, semaglutid gibi peptit ila\u00e7lar, hedefe y\u00f6nelik, uzun etkili ve ki\u015fiselle\u015ftirilebilir tedavi<\/strong> vizyonunu ger\u00e7e\u011fe d\u00f6n\u00fc\u015ft\u00fcrmektedir.<\/p>\n

            \u00d6n\u00fcm\u00fczdeki y\u0131llarda, GLP-1\u2019e ek olarak GIP ve glukagon resept\u00f6rlerini de hedefleyen \u00e7oklu agonistlerin, semaglutid\u2019in a\u00e7t\u0131\u011f\u0131 bu yolu daha da geni\u015fletmesi beklenmektedir. Ancak bug\u00fcn i\u00e7in, \u201cGLP-1 resept\u00f6r agonisti semaglutid\u201d obezite tedavisinde protein-temelli bir ila\u00e7 devriminin en g\u00f6r\u00fcn\u00fcr y\u00fcz\u00fc<\/strong> durumundad\u0131r.<\/p>\n

            Kaynaklar (Se\u00e7ilmi\u015f Akademik \u00c7al\u0131\u015fmalar)<\/h3>\n
              \n
            • Marso SP et al. N Engl J Med. 2016;375:1834\u20131844. doi:10.1056\/NEJMoa1607141<\/strong><\/li>\n
            • Granhall C et al. Diabetes Obes Metab. 2018;20(8):1885\u20131894. doi:10.1111\/dom.12765<\/strong><\/li>\n
            • Wilding JPH et al. N Engl J Med. 2021;384:989\u20131002. doi:10.1056\/NEJMoa2032183<\/strong><\/li>\n
            • Davies M et al. Lancet. 2017;390(10107):276\u2013290. doi:10.1016\/S0140-6736(17)31412-0<\/strong><\/li>\n
            • Rubino DM et al. Lancet. 2021;397(10278):971\u2013984. doi:10.1016\/S0140-6736(21)01751-5<\/strong><\/li>\n
            • Jastreboff AM et al. Nat Med. 2021;27:2072\u20132081. doi:10.1038\/s41591-021-01324-6<\/strong><\/li>\n<\/ul>\n

              Semaglutid Hakk\u0131nda En \u00c7ok Sorulan Sorular<\/h2>\n

              1. Semaglutid ile ne kadar s\u00fcrede kilo verilir?<\/h3>\n

              Genellikle ilk birka\u00e7 haftada i\u015ftah azalmas\u0131 ve hafif kilo kayb\u0131 ba\u015flar. Klinik \u00e7al\u0131\u015fmalarda, 6\u201312 ay i\u00e7inde v\u00fccut a\u011f\u0131rl\u0131\u011f\u0131n\u0131n ortalama %10\u201315\u2019ine varan kay\u0131plar bildirilmi\u015ftir (doi:10.1056\/NEJMoa2032183)<\/strong>. Ancak h\u0131z ve miktar; ba\u015flang\u0131\u00e7 kilosu, ya\u015fam tarz\u0131 de\u011fi\u015fiklikleri ve doz \u015femas\u0131na ba\u011fl\u0131 olarak ki\u015fiden ki\u015fiye de\u011fi\u015fir.<\/p>\n

              2. Semaglutid sadece obezite i\u00e7in mi, diyabetim yoksa da kullanabilir miyim?<\/h3>\n

              Evet, semaglutid hem diyabetli hem de diyabeti olmayan obez bireylerde kilo kayb\u0131 i\u00e7in \u00e7al\u0131\u015f\u0131lm\u0131\u015f ve onay alm\u0131\u015f formlara sahiptir. Ancak her durumda hekim de\u011ferlendirmesi ve re\u00e7etesi zorunludur.<\/p>\n

              3. Semaglutid tedavisi b\u0131rak\u0131ld\u0131\u011f\u0131nda kilo geri al\u0131n\u0131r m\u0131?<\/h3>\n

              \u00c7o\u011fu \u00e7al\u0131\u015fmada, semaglutid kesildi\u011finde i\u015ftah\u0131n k\u0131smen geri d\u00f6nd\u00fc\u011f\u00fc ve bir miktar kilo geri al\u0131m\u0131n\u0131n g\u00f6r\u00fclebildi\u011fi rapor edilmi\u015ftir. Kal\u0131c\u0131 kilo kontrol\u00fc i\u00e7in beslenme, fiziksel aktivite ve davran\u0131\u015f de\u011fi\u015fikli\u011fi<\/strong> ile desteklenmesi kritik \u00f6nemdedir.<\/p>\n

              4. Semaglutid k\u00fc\u00e7\u00fck molek\u00fcl m\u00fc, biyolojik (protein-peptit) bir ila\u00e7 m\u0131?<\/h3>\n

              Semaglutid, modifiye edilmi\u015f bir peptit yap\u0131l\u0131 biyolojik ila\u00e7t\u0131r<\/strong>; yani k\u00fc\u00e7\u00fck molek\u00fcl de\u011fildir. GLP-1 hormonuna benzer \u015fekilde tasarlanm\u0131\u015f ve kimyasal olarak stabilize edilmi\u015ftir; bu sayede uzun etkili ve hedefe y\u00f6nelik bir farmakolojik profil sunar.<\/p>\n

              5. Semaglutid kullananlarda en s\u0131k g\u00f6r\u00fclen yan etkiler nelerdir?<\/h3>\n

              En s\u0131k bildirilen yan etkiler bulant\u0131, kusma, ishal, kab\u0131zl\u0131k ve kar\u0131n a\u011fr\u0131s\u0131 gibi gastrointestinal \u015fik\u00e2yetlerdir<\/strong>. Genellikle doz yava\u015f art\u0131r\u0131ld\u0131\u011f\u0131nda daha hafif seyreder ve zamanla azal\u0131r. Nadir fakat ciddi yan etkiler (pankreatit, safra kesesi sorunlar\u0131 gibi) a\u00e7\u0131s\u0131ndan hekim takibi \u00f6nemlidir (doi:10.1111\/dom.12765)<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

              Semaglutid, GLP-1 resept\u00f6r agonistleri aras\u0131nda tip 2 diyabet ve obezite tedavisinde \u00f6ne \u00e7\u0131kan, protein-peptit yap\u0131l\u0131 yeni nesil bir biyolojik ila\u00e7t\u0131r. Etki mekanizmas\u0131n\u0131, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan farklar\u0131n\u0131 ve i\u015ftah kontrol\u00fc ile kilo kayb\u0131na nas\u0131l katk\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 ke\u015ffedin.<\/p>\n","protected":false},"author":1,"featured_media":10293,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91],"tags":[846,794,791],"class_list":["post-10292","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-enzimler-biyokimya","tag-glp-1-reseptor-agonisti","tag-obezite-tedavisi","tag-semaglutid"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10292"}],"version-history":[{"count":2,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10292\/revisions"}],"predecessor-version":[{"id":10296,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10292\/revisions\/10296"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/media\/10293"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}